Table 2.
Participant ELISpot responder details.
| Participant data | HIV-1 positive | HIV-1 positive | |||||
|---|---|---|---|---|---|---|---|
| Non-pregnant | Pregnant | ||||||
| Participants | Participants | ||||||
| (PnP) | (PP) | ||||||
| Number | 11 | 18 |
Chi squared (P-value) |
||||
| Gag | Nef | Gag | Nef | Gag | Nef | ||
| ELISpot responses above positivity threshold | IFNγ | 10/11 (91%) | 8/11 (73%) | 15/18 (83%) | 14/18 (78%) | 0.5659 | 0.7578 |
| IL-2 | 11/11 (100%) | 6/11 (55%) | 18/18 (100%) | 13/18 (72%) | 0.9999 | 0.3312 | |
| IL-10 | 5/11 (45%) | 9/11 (82%) | 13/18 (72%) | 17/18 (94%) | 0.1494 | 0.2787 | |
| Granzyme B | 6/11 (55%) | 7/11 (64%) | 14/18 (78%) | 10/18 (56%) | 0.1895 | 0.6681 | |
This table shows participant ELISpot responses that were above threshold for positivity of non-pregnant and pregnant HIV-1 positive women, with responder frequencies compared using Chi squared analysis. Responder numbers are shown with (frequency) given in parentheses. ELISpot responder numbers are from time of consent/first sample time-point. Italics are to differentiate p-values from data. Statistical significance was defined using p-values shown as: * when p < 0.05, ** when p ≤ 0.01, *** when p ≤ 0.001, and **** when p ≤ 0.0001.